Bone marrow metastases

[Correlation of hematologic parameters with bone marrow and spleen uptake in FDG PET]

OBJECTIVE

To assess the relationship between various hematologic parameters and bone marrow (BM) and splenic uptake of FDG in PET imaging.

MATERIAL AND METHODS

29 patients with Hodgkin's disease (HD) referred for baseline FDG PET imaging before treatment and without evidence of bone marrow (BM) involvement were included in the study. Splenic uptake also was analyzed in 18 patients without splenic involvement. BM and splenic activity were visually graded on a 3 point scale. Activity pattern was classified as homogeneous or heterogeneous. Semi-quantitative analysis was also performed by drawing regions of interest (ROI) over the spine and spleen. ROIs also were drawn over right lung and liver. FDG uptake ratios for the spine and spleen in comparison with the lung and liver were generated. Visual scoring of marrow and splenic uptake, and the various ratios were correlated with hemoglobin (Hb), white blood cell (WBC), and platelet counts, and correlation coefficients were calculated.

RESULTS

In 27/29 patients (93 %) BM and in 18/18 patients (100 %) spleen uptake was diffuse. There was a direct correlation between BM and spleen uptake of FDG with increasing WBC, which was stronger than the inverse correlation seen with Hb (the lower the Hb the greater the uptake). Correlation with platelet counts was weaker.

CONCLUSION

There is a correlation between hematologic parameters such as Hb, WBC and platelet counts and the uptake of FDG in BM and spleen in PET imaging. Knowledge of this correlation should help to better interpret and understand PET imaging.

Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial

Tumor contamination of autologous peripheral blood stem/progenitor cell grafts occurs in a substantial proportion of high-risk breast cancer patients, and the possibility that such contamination may contribute to relapse has focused attention on methods for removal of the contaminating cells prior to transplantation. One such approach is positive selection of CD34+ cells. A fully automated immunomagnetic cell selection system has recently been introduced to facilitate the positive selection process. A multicenter randomized clinical trial was designed to evaluate the capacity of CD34+ cells isolated using the fully automated system to support prompt hematopoietic reconstitution following high-dose chemotherapy in high-risk breast cancer patients, as well as to assess the safety and tolerability of the CD34+ cell transplants. In recipients of isolated CD34+ cells, the median time to an absolute neutrophil count > or =500/microl was 10 days, a value identical to that observed in patients receiving unfractionated apheresis collections. In the isolated CD34+ cell recipients median time to a platelet count > or =20 000/microl was 12 days, compared with 10 days in the unfractionated cell group. There were no statistically significant differences between the groups in median time to neutrophil or platelet engraftment. Infusion of autologous cells was well tolerated by the study groups. There were no inter-group differences in the incidence of infections, need for platelet transfusions, or duration of hospitalization. Isolated CD34+ cells were high in purity and sufficient in number for use in autologous transplantation. The fully automated immunomagnetic cell selection system affords an efficient and time-saving option for isolation of CD34+cells to be used as autologous grafts in high-risk breast cancer patients, and the isolated CD34+ cells support undelayed hematopoietic reconstitution.